Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Peter M Szabo"'
Autor:
Mario Sznol, Toni K Choueiri, Scott D Chasalow, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Alice M Walsh, Megan Wind-Rotolo, Ron Ammar, Peter M Szabo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunothera
Externí odkaz:
https://doaj.org/article/2e6e7ac70cb64051a3880d53c7fc409f
Autor:
Gábor Kemenesi, Safia Zeghbib, Balázs A Somogyi, Gábor Endre Tóth, Krisztián Bányai, Norbert Solymosi, Peter M Szabo, István Szabó, Ádám Bálint, Péter Urbán, Róbert Herczeg, Attila Gyenesei, Ágnes Nagy, Csaba István Pereszlényi, Gergely Csaba Babinszky, Gábor Dudás, Gabriella Terhes, Viktor Zöldi, Róbert Lovas, Szabolcs Tenczer, László Kornya, Ferenc Jakab
Publikováno v:
Viruses, Vol 12, Iss 12, p 1401 (2020)
Severe Acute Respiratory Syndrome Coronavirus 2 is the third highly pathogenic human coronavirus in history. Since the emergence in Hubei province, China, during late 2019, the situation evolved to pandemic level. Following China, Europe was the seco
Externí odkaz:
https://doaj.org/article/175a02c738704eeaa235c743bc3378f6
Autor:
Li Wang, Abdel Saci, Peter M. Szabo, Scott D. Chasalow, Mireia Castillo-Martin, Josep Domingo-Domenech, Arlene Siefker-Radtke, Padmanee Sharma, John P. Sfakianos, Yixuan Gong, Ana Dominguez-Andres, William K. Oh, David Mulholland, Alex Azrilevich, Liangyuan Hu, Carlos Cordon-Cardo, Hélène Salmon, Nina Bhardwaj, Jun Zhu, Matthew D. Galsky
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Although T-cell infiltration is correlated with EMT-related gene expression in urothelial cancer specimens, here, the authors report EMT-related signatures in urothelial cancer arise mainly from stromal cells. Increased EMT-related gene expression in
Externí odkaz:
https://doaj.org/article/0e94d49acf9b403fa3f22b69087eb769
Autor:
James H. Doroshow, Richard M. Simon, Barbara A. Conley, Robert J. Kinders, P. Mickey Williams, Seth M. Steinberg, Paul M. McGregor, William D. Walsh, Michele G. Mehaffey, Chih-Jian Lih, Deborah E. Allen, Jiuping Ji, Alice P. Chen, Ahrim Youn, Peter M. Szabo, Robert J. Morgan, Miguel A. Villalona-Calero, Michael J. Naughton, David R. Gandara, Daniel M. Sullivan, Gini F. Fleming, Amit M. Oza, Shivaani Kummar
Supplemental Figure S1. Kaplan-Meier analysis of the progression free survival (PFS) of patients on each treatment arm stratified by BRCA status showed no significant differences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac78b660c4e98ad73ca9863a9f1c1ebb
https://doi.org/10.1158/1078-0432.22461263.v1
https://doi.org/10.1158/1078-0432.22461263.v1
Autor:
Zachary Boyd, Ian Chau, Filippo de Braud, Thomas R. Jeffry Evans, Johanna Bendell, Padmanee Sharma, Patrick A. Ott, Yelena Janjigian, Peter M. Szabo, Christopher Harbison, Teresa Sanchez, Han Chang, Dimple Pandya, Nathan O. Siemers, Ming Lei
Supplementary Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9522537b32eed18f18dcf3a1c1097324
https://doi.org/10.1158/1078-0432.22481259.v1
https://doi.org/10.1158/1078-0432.22481259.v1
Autor:
Padmanee Sharma, Andrea Necchi, Arlene Siefker-Radtke, Sandra Collette, Gary Grossfeld, G. Celine Han, Peter M. Szabo, Abdel Saci, Matthew D. Galsky
This appendix includes all supplemental tables and figures referenced in the article.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54365bbaa6e8ee8af854bcfc9a0700b5
https://doi.org/10.1158/1078-0432.22476537
https://doi.org/10.1158/1078-0432.22476537
Autor:
Zachary Boyd, Ian Chau, Filippo de Braud, Thomas R. Jeffry Evans, Johanna Bendell, Padmanee Sharma, Patrick A. Ott, Yelena Janjigian, Peter M. Szabo, Christopher Harbison, Teresa Sanchez, Han Chang, Dimple Pandya, Nathan O. Siemers, Ming Lei
Purpose:In advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC), there is a need to identify biomarkers of response to therapies, such as immune checkpoint inhibitors.Patients and Methods:In post hoc exploratory analyses from CheckMate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87927031a61e65f5923467f0c87959b
https://doi.org/10.1158/1078-0432.c.6530646.v1
https://doi.org/10.1158/1078-0432.c.6530646.v1
Autor:
Zachary Boyd, Ian Chau, Filippo de Braud, Thomas R. Jeffry Evans, Johanna Bendell, Padmanee Sharma, Patrick A. Ott, Yelena Janjigian, Peter M. Szabo, Christopher Harbison, Teresa Sanchez, Han Chang, Dimple Pandya, Nathan O. Siemers, Ming Lei
Gene expression levels by cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80f09d1681d4fbca853b5013a2d27119
https://doi.org/10.1158/1078-0432.22481250.v1
https://doi.org/10.1158/1078-0432.22481250.v1
Autor:
James H. Doroshow, Richard M. Simon, Barbara A. Conley, Robert J. Kinders, P. Mickey Williams, Seth M. Steinberg, Paul M. McGregor, William D. Walsh, Michele G. Mehaffey, Chih-Jian Lih, Deborah E. Allen, Jiuping Ji, Alice P. Chen, Ahrim Youn, Peter M. Szabo, Robert J. Morgan, Miguel A. Villalona-Calero, Michael J. Naughton, David R. Gandara, Daniel M. Sullivan, Gini F. Fleming, Amit M. Oza, Shivaani Kummar
Supplementary Expression Data. Individual expression values for all 211 genes interrogated in the tumor tissue of 55 patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4719fdaa52cff5b2368e357113fb40cf
https://doi.org/10.1158/1078-0432.22461254
https://doi.org/10.1158/1078-0432.22461254
Autor:
James H. Doroshow, Richard M. Simon, Barbara A. Conley, Robert J. Kinders, P. Mickey Williams, Seth M. Steinberg, Paul M. McGregor, William D. Walsh, Michele G. Mehaffey, Chih-Jian Lih, Deborah E. Allen, Jiuping Ji, Alice P. Chen, Ahrim Youn, Peter M. Szabo, Robert J. Morgan, Miguel A. Villalona-Calero, Michael J. Naughton, David R. Gandara, Daniel M. Sullivan, Gini F. Fleming, Amit M. Oza, Shivaani Kummar
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of PARP inhibition to the observed clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a59e143b68831612282f14d975a5acd
https://doi.org/10.1158/1078-0432.c.6524744.v1
https://doi.org/10.1158/1078-0432.c.6524744.v1